Browse the evidence

GLP-1 receptor agonists (specifically semaglutide 2.4 mg/week and liraglutide 3.0 mg/day) produce significant weight loss in adults with obesity (BMI ≥27 or ≥30) when combined with lifestyle modifications, outperforming placebo and many other pharmacotherapies.

If you have obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, GLP-1 agonists like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with diet and exercise. Semaglutide showed an average loss of 15.3 kg over 68 weeks in trials. Expect mild, temporary gastrointestinal side effects, but these rarely require stopping treatment. Oral options exist for those averse to injections.

GLP-1 receptor agonists (semaglutide 2.4 mg and liraglutide 3.0 mg) reduce energy intake by 34.5% and 13.0% respectively, leading to estimated body weight reductions of 17% and 8% at 20 weeks.

Clinical doses of GLP-1 agonists (semaglutide 2.4mg, liraglutide 3.0mg) significantly reduce energy intake, leading to substantial weight loss (8-17%) over 20 weeks. This effect is primarily driven by reduced food intake rather than just increased energy expenditure, and the model accounts for diminishing efficacy (tolerance) over time.

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that promotes weight loss and glycemic control through synergistic mechanisms including increased glucose-dependent insulin secretion, reduced glucagon, delayed gastric emptying, and increased satiety.

Tirzepatide is a powerful, weekly injectable medication for diabetes and obesity that works by mimicking hormones to control blood sugar and reduce appetite. It requires a prescription, medical supervision, and lifestyle changes (diet/exercise). Using it without medical oversight for aesthetic reasons is dangerous and contributes to drug shortages and fraud.

Dual incretin agonists (specifically GIP/GLP-1 co-agonists like tirzepatide) produce significantly greater weight loss and glycemic reduction than single GLP-1 receptor agonists, effectively closing the treatment gap between pharmacotherapy and bariatric surgery.

If standard GLP-1 medications (like semaglutide or liraglutide) are not delivering sufficient weight loss or blood sugar control, or if side effects prevent you from taking a higher dose, ask your doctor about dual agonists like tirzepatide. These medications target two hormones (GIP and GLP-1) simultaneously and have shown in clinical trials to produce significantly greater weight loss (up to 20%) and better blood sugar control than single-hormone drugs, often with a manageable side effect profile.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces significant weight loss (15-21%) in adults with obesity when administered weekly alongside lifestyle modifications.

If you have obesity or are overweight with related health issues, Tirzepatide is a once-weekly injection that works by mimicking hormones to reduce appetite and slow digestion. In clinical trials, patients lost 15-21% of their body weight over 72 weeks when combining the drug with diet and exercise. While nausea and diarrhea are common side effects, they affect a minority of users. This treatment is intended for long-term management, not short-term fixes.

GLP-1 receptor agonists (semaglutide, liraglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce significant weight loss (5-21%) by suppressing appetite via central nervous system mechanisms and delaying gastric emptying, serving as effective pharmacological alternatives to surgery.

If diet and exercise aren't enough, GLP-1 drugs like Semaglutide (Wegovy) or Tirzepatide (Zepbound) are highly effective pharmacological options. They work by mimicking gut hormones to reduce hunger signals in the brain and slow down digestion. Semaglutide is taken once weekly, while Tirzepatide (a dual agonist) can lead to even greater weight loss (up to 21%). These require a prescription and lifestyle changes, and may cause gastrointestinal side effects like nausea.

Tirzepatide treatment for weight management produces significant weight loss (mean 22.6% over 36 weeks) accompanied by perceived improvements in appetite control, energy levels, and physical functioning, with gastrointestinal side effects being common but generally manageable.

Tirzepatide is a weekly injection approved for weight management in adults with obesity or overweight. Clinical data from the SURMOUNT-4 trial shows an average weight loss of 22.6% over 36 weeks. Patients report significant improvements in appetite control, energy, and physical functioning. Common side effects include nausea and diarrhea, which are often manageable. Most patients found the injection device easy to use and were willing to continue treatment.

Subcutaneous semaglutide 2.4 mg administered once weekly significantly reduces body weight and cardiometabolic risk factors (HbA1c, total cholesterol, systolic blood pressure) in East Asian adults with obesity compared to placebo, though it is associated with higher rates of adverse events.

For East Asian adults with obesity, once-weekly subcutaneous semaglutide (2.4 mg) combined with diet and exercise is a clinically effective treatment for significant body weight reduction and improvement in cardiometabolic risk factors like blood pressure and cholesterol. Patients should be aware that adverse events are more common than with placebo, but the clinical benefits are established.

Tirzepatide (a dual GLP-1RA/GIP agonist) produces superior mean weight loss (18.4%) compared to other FDA-approved pharmacotherapies for obesity, including semaglutide, phentermine-topiramate, and orlistat.

If you have obesity and lifestyle changes alone haven't worked, Tirzepatide is currently the most effective FDA-approved medication for weight loss, showing nearly 18% average weight loss in clinical trials. It requires weekly injections and careful dose titration to manage gastrointestinal side effects, but it offers superior results compared to older drugs like Orlistat or Phentermine-Topiramate.

Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.

Semaglutide is a highly effective weekly injection for weight loss, averaging 10-12% loss in clinical trials. It is more effective than older drugs like Orlistat or Phentermine-Topiramate and also improves heart health markers. It requires weekly injections and titration to manage side effects.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.

If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.

Weekly tirzepatide injections combined with dietician support reduce OSA severity by approximately 50% in obese patients with moderate to severe OSA.

If you are obese and have moderate to severe sleep apnea, ask your doctor about tirzepatide. This weekly injection, combined with dietary support, has been shown to cut your apnea severity in half. It is FDA-cleared for this use and may improve your blood pressure and sleep quality, though you should expect some mild stomach issues initially.

Melanocortin-4 receptor (MC4R) agonists significantly reduce body weight, BMI, and hunger scores in patients with obesity, including those with rare genetic syndromes.

If you have obesity, particularly if it is linked to a rare genetic condition, MC4R agonist drugs like setmelanotide can significantly reduce your body weight, BMI, and hunger. These drugs work by activating receptors in your brain that control satiety and energy expenditure. Treatment involves daily subcutaneous injections, with doses adjusted based on your age and how well you tolerate the medication. While lifestyle changes are important, they often lead to modest and unsustainable weight loss, making these drugs a valuable option for those who struggle with conventional methods.

GLP-1 receptor agonists reduce food intake, increase satiety, delay gastric emptying, and improve glucose tolerance, leading to weight loss in humans.

GLP-1 receptor agonists are a proven, FDA-approved treatment for obesity and type 2 diabetes. They work by reducing appetite and improving metabolic function. Consult a healthcare provider to see if this treatment is appropriate for you.

Orforglipron 45 mg significantly reduces BMI, body weight, waist circumference, and HbA1c in patients with T2DM or obesity, with efficacy increasing at higher doses.

If you have T2DM or obesity, the 45 mg dose of oral orforglipron is highly effective for reducing weight and blood sugar. It works by mimicking a gut hormone to control appetite and insulin. Expect significant results, but be aware of potential side effects like nausea.

Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.

Next-generation GLP-1 based therapies aim to achieve greater weight loss (>25%), improved tolerability, and novel delivery platforms, including oral formulations and small-molecule agonists. These therapies are currently in clinical trials and represent the future direction of obesity treatment.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and tirzepatide are effective first-line pharmacological treatments for obesity in psoriasis patients, providing significant weight loss and independent improvements in psoriasis severity (PASI scores) through anti-inflammatory mechanisms.

If you have psoriasis and obesity, GLP-1 drugs like semaglutide or tirzepatide are highly effective first-line treatments. They help you lose significant weight and can directly reduce your psoriasis severity, not just through weight loss but by lowering inflammation. Start with lifestyle changes, but if you need medication, these drugs are safe and effective. Work with your doctor to find the right dose and manage any initial stomach side effects by starting low and going slow.

GLP-1 agonist semaglutide produces significant weight loss (12.7%) and improves cardiometabolic risk in adults with obesity, with transient mild-to-moderate nausea and diarrhea as primary side effects.

If you have obesity and meet the criteria (BMI ≥30 or ≥27 with complications), discuss GLP-1 agonists like semaglutide with your doctor. This medication can lead to substantial weight loss (around 12.7% in studies) and improves blood sugar and heart disease risk. Common side effects like nausea or diarrhea are usually temporary and manageable.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce significant weight loss (6.2–15.8 kg) in adults with obesity, with efficacy increasing with higher doses.

GLP-1 agonists like semaglutide and liraglutide are effective for significant weight loss in adults with obesity, often outperforming lifestyle changes alone. Expect weight loss between 6-16 kg over several months. Be aware of gastrointestinal side effects, which are common but often manageable. These are prescription medications requiring medical supervision to manage dosing and side effects.

Semaglutide (2.4 mg weekly) produces significant weight loss (10-15%) in adults with obesity by slowing gastric emptying and reducing appetite, but discontinuation leads to substantial weight regain, necessitating continuous treatment.

Semaglutide 2.4mg weekly is a highly effective tool for significant weight loss (10-15%) in obesity, working by reducing appetite and slowing digestion. However, it is not a cure; stopping the medication typically leads to regaining most of the lost weight. It works best when combined with lifestyle changes and requires ongoing medical supervision to manage side effects like nausea and to ensure long-term success.

Semaglutide 2.4 mg administered once weekly produces significant weight loss (mean 14.9%) in adults with obesity or overweight, superior to placebo, when combined with lifestyle interventions.

Semaglutide 2.4mg weekly, combined with diet and exercise, leads to substantial weight loss (approx 15%) in obese adults without diabetes. Expect potential nausea, which often subsides. It is more effective than older drugs like orlistat and requires weekly injection rather than daily.

GLP-1 receptor agonists (GLP1RAs) such as semaglutide and liraglutide induce significant weight loss (5-15%) and improve metabolic markers by delaying gastric emptying, suppressing appetite via central nervous system signaling, and enhancing glucose-dependent insulin secretion.

GLP-1 medications like semaglutide and liraglutide are highly effective for weight loss (5-22%) and metabolic health. They work by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize nausea, which usually improves over time. Combine with a calorie-controlled diet and exercise for best results. Oral versions exist but may have different absorption requirements.